
-
Avadel Pharmaceuticals plc NasdaqGM:AVDL Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Location: 10 Earlsfort Terrace, Ballycoolin, Dublin 2, D02 T380, Ireland | Website: https://www.avadel.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
901.6M
Cash
66.48M
Avg Qtr Burn
-6.359M
Short % of Float
11.99%
Insider Ownership
4.92%
Institutional Own.
83.57%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LUMRYZ (sodium oxybate) Details Excessive daytime sleepiness, Narcolepsy | Approved Quarterly sales | |
LUMRYZ (sodium oxybate) Details Narcolepsy, Excessive daytime sleepiness, Cataplexy | Approved Quarterly sales | |
LUMRYZ (sodium oxybate) Details Idiopathic hypersomnia | Phase 3 Data readout |